Cellectar Biosciences
CLRB
5 hedge funds and large institutions have $8.3M invested in Cellectar Biosciences in 2015 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
21% more capital invested
Capital invested by funds: $6.87M → $8.3M (+$1.43M)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
17% less funds holding
Funds holding: 6 → 5 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$80.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Sophrosyne Capital
New York
|
-$441K |
| 2 |
Goldman Sachs
New York
|
-$80.3K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
-$44K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIC
1
AWM Investment Company
New York
| $4.38M | – | – | – |
|
|
SM
2
Sabby Management
Miami Beach,
Florida
| $2.02M | +$80.3K | +1 | +5% |
|
|
CAM
3
Cormorant Asset Management
Boston,
Massachusetts
| $1.65M | – | – | – |
|
|
BA
4
Bard Associates
Chicago,
Illinois
| $134K | – | – | – |
|
|
5
Goldman Sachs
New York
| $74K | -$80.3K | -1 | -50% |
|
6
Morgan Stanley
New York
| $34K | – | – | – |
|
7
Bank of America
Charlotte,
North Carolina
| $3K | – | – | – |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $3K | – | – | – |
|
|
SSB
9
Sandy Spring Bank
Olney,
Maryland
| $2K | – | – | – |
|
|
AIG
10
American International Group
New York
| $16 | – | – | – |
|
|
SC
11
Sophrosyne Capital
New York
| – | -$441K | -5 | Closed |
|
|
VKH
12
Virtu KCG Holdings
New York
| – | -$44K | – | – |
|
CLRB Hedge Fund Activity: Q1 2015 in Review
5 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q1 2015, worth a combined $8.3M — up 21% from $6.87M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of CLRB and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 1 added.
The largest buyer was Sabby Management, adding an estimated $80.3K. The largest seller was Sophrosyne Capital, exiting entirely with an estimated $441K sold.
- 5 institutional investors held Cellectar Biosciences (CLRB) as of Q1 2015, down from 6 in Q4 2014.
- Funds reported $8.3M of Cellectar Biosciences stock for Q1 2015, up 21% quarter-over-quarter.
- 0 funds opened new Cellectar Biosciences positions in Q1 2015 and 1 closed out, a net change of -1 holder.
- The largest Cellectar Biosciences buyer in Q1 2015 was Sabby Management, an estimated $80.3K added.
- The largest Cellectar Biosciences seller in Q1 2015 was Sophrosyne Capital, an estimated $441K sold.
Based on aggregated 13F filings for Q1 2015.